This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AAV-FANCC (Stanford)

Abeona Therapeutics, Inc.

Description: Abeona is developing an adeno-associated virus (AAV) gene therapy program expressing LK19 FANCC for the treatment of Fanconi anemia.

Deal Structure: Stanford and Abeona
In September 2015, Abeona announced a license agreement with Stanford University for an AAV (adeno-associated virus) delivery vector for the treatment of Fanconi anemia (FA) and rare blood disease platform.

AAV-FANCC (Stanford) News

Scrip Ethics

Pink Sheet Ethics

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug